Kymera Therapeutics Inc stock is traded at $128.12, with a volume of 1,728,951. It is down -5.97% in the last 24 hours and up +20.89% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Previous Close:
$136.25
Open:
$137.54
24h Volume:
1,728,951
Relative Volume:
1.51
Market Cap:
$10.94B
Revenue:
$51.48M
Net Income/Loss:
-$315.00M
P/E Ratio:
-
EPS:
-$3.57
Net Cash Flow:
-$244.00M
1W Performance:
+1.18%
1M Performance:
+20.89%
6M Performance:
+48.53%
1Y Performance:
+110.03%
1-Day Range:
$0.00$0.00
1-Week Range:
$124.22$138.00
52-Week Range:
$56.75$138.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
857-285-5314Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS